MBio Diagnostics’ proprietary optical technology is the core of our highly-sensitive testing system developed to provide the immediate, reliable information needed to improve clinical decisions. Our platform was established for the diagnosis of high impact infectious diseases, and in conjunction with key partners and collaborators, is being tested and evaluated for these and other new applications around the world. Here are examples of some of MBio’s key collaborations:
University of California, San Diego (UCSD):
Contributing global health and viral disease expertise
MBio Diagnostics has developed a longstanding collaboration with a team of world class clinical infectious disease experts at the University of California, San Diego (UCSD).
Dr. Robert Schooley is a globally-recognized AIDS and viral disease expert and is Head of the Division of Infectious Diseases, Executive Vice Chairman of the UCSD Department of Medicine and Associate Director of the UCSD Center for AIDS Research. He is a member of the US Department of State’s PEPFAR Scientific Advisory Board and serves as Chairman of the NIH’s Drug Discovery and Resistance Study Section of the National Institutes of Health. He actively advises MBio on test approaches.
Dr. Constance Benson is Professor of Medicine and Director of the UCSD Antiviral Research Center (AVRC) and served as Chair of the Executive Committee of the NIH/NIAID AIDS Clinical Trials Group (ACTG) from 2002-2010. She is a member of the IAS-USA Panel on HIV Therapeutics. Dr. Benson provides guidance to MBio on clinical testing protocols and trial design.
MBio Diagnostics and the UCSD clinical team have several ongoing research collaborations, including multiple programs funded by the NIH. UCSD and the Antiviral Research Center in San Diego serve as clinical evaluation sites of various MBio assays and devices. MBio Diagnostics also benefits from the global network of infectious disease researchers and sites coordinated by Drs. Schooley and Benson.
Delivering high-impact, low-cost solutions to transform global healthPATH is an international nonprofit organization that transforms global health through innovation. They focus their work on advancing technologies, strengthening systems, and encouraging healthy behaviors around the world by taking an entrepreneurial approach to developing and delivering high-impact, low-cost solutions — from lifesaving vaccines and devices to collaborative programs with communities. Through their work in more than 70 countries, PATH, together with partners such as MBio Diagnostics, respond to the spectrum of global health needs. In particular, they focus on:
- Solutions for emerging and epidemic diseases, like AIDS and tuberculosis.
- Health technologies designed for low-resource settings, by the people who will use them.
- Safer childbirth and healthy children.
- Health equity for women, among the world’s most vulnerable—and influential—populations.
MBio Diagnostics is in a multi-year collaboration with PATH’s Center for Point-of-Care Diagnostics for Global Health focused on MBio’s point-of-care infectious diseases platform, specifically focusing on HIV and syphilis testing of pregnant women. After a successful one-year evaluation of the MBio development platform in the PATH laboratory in Seattle, field evaluations in western Kenya were initiated in early 2012. The pre-market evaluation in Kenya will provide MBio with operational feedback on the system prior to finalizing product design.
Foundation for Innovative New Diagnostics (FIND):
Addressing poverty-related diseases including tuberculosis
The Foundation for Innovative New Diagnostics (FIND) builds and sustains effective partnerships in order to address the urgent need for better diagnostic tests for poverty-related diseases, including tuberculosis. FIND’s latest test for TB and drug resistance, endorsed by the World Health Organization (WHO) in December 2010, has the potential to revolutionize TB care and control in the countries and populations most affected by the disease. Click here to read the WHO press release.
FIND and MBio are collaborating in a project to evaluate how MBio’s multiplexing technology might enable rapid and effective analysis of 60 blood-based markers for TB. This work could, if it proves promising, lead to the development of a completely new approach to testing for this difficult to diagnose disease.
Leveraging multiplexing potential with novel applications
MBio supports BEACONS (Biosafety for Environmental Contaminants using Novel Sensors), a joint development project that is part of a United States – Ireland Partnership Program sponsored in the U.S by the National Science Foundation; in Ireland by the Science Foundation, Ireland; and in Northern Ireland by the Department of Employment and Learning. The project focuses development of prototype sensor instruments for selected toxins in the food supply chain. The consortium includes researchers at Queen’s University Belfast and Dublin City University in Ireland as well as the National Oceanic and Atmospheric Administration (NOAA) and the University of Maine in the United States.
MBio provides instrumentation and assay development support to this international research team. Through this life science collaboration, MBio demonstrates a novel use of MBio’s core diagnostic technology by applying the diagnostic system for algal biotoxin detection.
From our initial success in building technology and collaborations in the area of infectious disease, we are developing a range of simple, multiplexed diagnostics tests that can be adapted to these and other medical and life sciences applications, and are evaluating additional collaborations in Europe and Asia for further studies. For more information on those initiatives, or to collaborate with us, contact us.